Molecular Tumor Board: 77-year-old female with metastatic breast cancer with PIK3CA H1047R mutation and 83-year-old female with metastatic breast cancer with AKT1 L52R mutation

Dr. Marcela Mazo Canola, Assistant Professor of Medicine, Breast Medical Oncology at UT Health San Antonio Mays Cancer Center joined our Oncology Medical Affairs Directors, Kyle Strickland and Heidi Ko to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. Two cases of metastatic hormone receptor-positive, HER2-negative breast cancer with PIK3CA and AKT1 alterations were discussed. The pivotal clinical trials leading to the approval of targeted therapies for these alterations, side effect profiles, testing workflows for biomarker-guided therapy in HR+ breast cancer were reviewed.